Compounds > enkephalin--ala(2)-mephe(4)-gly(5)-

enkephalin--ala(2)-mephe(4)-gly(5)- and Parkinson-Disease

enkephalin--ala(2)-mephe(4)-gly(5)- has been researched along with Parkinson-Disease* in 2 studies

Other Studies

2 other study(ies) available for enkephalin--ala(2)-mephe(4)-gly(5)- and Parkinson-Disease

Article	Year
Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience, 1994, Volume: 61, Issue:1 The specific binding of [3H]neurotensin, [3H]substance P, [3H]D-Ala2-D-Leu5-enkephalin (delta receptors) and [3H]-Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (mu receptors) were studied in membrane preparations of caudate nucleus, putamen, globus pallidus and substantia nigra from patients with Parkinson's disease and from age-matched controls. The density of neurotensin receptors was decreased in globus pallidus (lateral and medial segments) in parkinsonian brain. Substance P receptors were reduced in the putamen (anterior and posterior) and in lateral globus pallidus in Parkinson's disease. There was a reduction in the density of opioid receptors in posterior putamen and in mu receptors in caudate nucleus and putamen (anterior and posterior). No differences in neuropeptide receptor binding were observed in substantia nigra from parkinsonian brains compared with control subjects. The reductions in neuropeptide receptor density were less marked than the decrease in caudate and putamen content of dopamine and its metabolites. This suggests that neuropeptide receptors are only partially localized to striatal dopamine terminals. Topics: Adult; Aged; Amino Acid Sequence; Analgesics; Basal Ganglia; Biogenic Monoamines; Dopamine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Female; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Sequence Data; Parkinson Disease; Receptors, Neurokinin-1; Receptors, Neurotensin; Receptors, Opioid, delta; Receptors, Opioid, mu	1994
Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. Brain research, 1987, Jun-23, Volume: 414, Issue:1 The binding properties of mu and delta opioid receptors were investigated in several areas of human brain by using [3H]Tyr-D-Ala-Gly-(Me)Phe-Gly-ol and [3H]Tyr-D-Thr-Gly-Phe-Leu-Thr as respective selective ligands, while the totality of opioid receptors was measured by using [3H]etorphine as a non-selective agonist. Receptor densities were highest in cerebral cortex, amygdala and striatum, and lowest in the substantia nigra (pars compacta). In the different brain areas of patients with Parkinson's disease, the density and the proportion of the various opioid receptors were not significantly different from control subjects. Topics: Aged; Aged, 80 and over; Brain; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Etorphine; Humans; Kinetics; Oligopeptides; Parkinson Disease; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu	1987

Article

Year

Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients.

Neuroscience, 1994, Volume: 61, Issue:1

The specific binding of [3H]neurotensin, [3H]substance P, [3H]D-Ala2-D-Leu5-enkephalin (delta receptors) and [3H]-Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (mu receptors) were studied in membrane preparations of caudate nucleus, putamen, globus pallidus and substantia nigra from patients with Parkinson's disease and from age-matched controls. The density of neurotensin receptors was decreased in globus pallidus (lateral and medial segments) in parkinsonian brain. Substance P receptors were reduced in the putamen (anterior and posterior) and in lateral globus pallidus in Parkinson's disease. There was a reduction in the density of opioid receptors in posterior putamen and in mu receptors in caudate nucleus and putamen (anterior and posterior). No differences in neuropeptide receptor binding were observed in substantia nigra from parkinsonian brains compared with control subjects. The reductions in neuropeptide receptor density were less marked than the decrease in caudate and putamen content of dopamine and its metabolites. This suggests that neuropeptide receptors are only partially localized to striatal dopamine terminals.

Topics: Adult; Aged; Amino Acid Sequence; Analgesics; Basal Ganglia; Biogenic Monoamines; Dopamine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Female; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Sequence Data; Parkinson Disease; Receptors, Neurokinin-1; Receptors, Neurotensin; Receptors, Opioid, delta; Receptors, Opioid, mu

1994

Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects.

Brain research, 1987, Jun-23, Volume: 414, Issue:1

The binding properties of mu and delta opioid receptors were investigated in several areas of human brain by using [3H]Tyr-D-Ala-Gly-(Me)Phe-Gly-ol and [3H]Tyr-D-Thr-Gly-Phe-Leu-Thr as respective selective ligands, while the totality of opioid receptors was measured by using [3H]etorphine as a non-selective agonist. Receptor densities were highest in cerebral cortex, amygdala and striatum, and lowest in the substantia nigra (pars compacta). In the different brain areas of patients with Parkinson's disease, the density and the proportion of the various opioid receptors were not significantly different from control subjects.

Topics: Aged; Aged, 80 and over; Brain; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Etorphine; Humans; Kinetics; Oligopeptides; Parkinson Disease; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu

1987